This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

CHARLES B. WITT, JR., M.D.

AMA Arch Surg. 1962;84(6):665-669.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

The earliest effective approach to thromboembolic disease made use of heparin and the coumarin drugs. Ideally, these agents should dissolve an existing thrombus, but their only therapeutic action lies in preventing an extension or embolization of the thrombus.¹ Their role in the actual prevention of recurrent thrombosis is subject to question in many series because of the lack of control clinical material. Much evidence is based on subjective findings, rather than objective data. None of the anticoagulant drugs satisfy the process of complete clot dissolution in vivo.^2-4 After several weeks the body may partially overcome the tissue damage, and recanalization may occur after injury.

With the realization that fibrin is the primary constituent of intravascular thrombi, and with the discovery of an intrinsic fibrinolytic system in plasma⁵ (which in the dog is more active than in the human), investigation surged forward to find the ideal agent.

Probably . . . [Full Text PDF of this Article]

Author Affiliations
LOS ANGELES

From the Department of Surgery, University of California Medical Center, and Department of Thoracic Surgery, Los Angeles County Harbor General Hospital, Torrance, Calif.

Footnotes
Received for publication July 7, 1961.

Supported by Grant-in-Aid No. H-2812, National Heart Institute, National Institutes of Health, Bethesda 14, Md.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?